Tremblay R R, Deperthes D, Têtu B, Dubé J Y
Department of Medicine, Laval University, Quebec, Canada.
Am J Pathol. 1997 Feb;150(2):455-9.
The development of monoclonal antibodies directed against prostatic kallikrein hK2 prompted us to evaluate its content, along with that of hK3 (prostate-specific antigen), in human prostate carcinoma. Seventy tumors categorized according to the M.D. Anderson Hospital classification (grade I to IV) were analyzed by immunohistochemistry. The staining intensity or the kallikrein content of benign prostatic hyperplasia glandular tissue (used as control) and of grade I tumors appeared similar. In grade II to IV tumors, histochemical data revealed highly variable hK2 or hK3 content in approximately 25% of tumors. Such patterns are consistent with a current observation related to heterogeneity of prostate tumors. In addition, a few tumors did not express hK3 (n = 3), hK2 (n = 3), or both (n = 3), indicating that some growth patterns of prostatic neoplasia are associated with a lack of secretion or storage of hK3 or hK2 for immunodetection. This statement also appears relevant to metastases. It was interesting to note that 4% of hK3-negative tumors had detectable hK2. Because of the importance of hK3 as a serum marker of prostate disorder, this study addresses for the first time the question of the relative importance of both hK3 and hK2 in the immunohistochemical diagnosis of prostatic tumors. We conclude that hK2 may add new information to prostate cancer diagnosis and characterization.
针对前列腺激肽释放酶hK2的单克隆抗体的研发促使我们评估其在人前列腺癌中的含量，以及hK3（前列腺特异性抗原）的含量。根据MD安德森医院分类（I级至IV级）对70个肿瘤进行了免疫组织化学分析。良性前列腺增生腺组织（用作对照）和I级肿瘤的激肽释放酶含量或染色强度相似。在II级至IV级肿瘤中，组织化学数据显示约25%的肿瘤中hK2或hK3含量高度可变。这些模式与目前有关前列腺肿瘤异质性的观察结果一致。此外，少数肿瘤不表达hK3（n = 3）、hK2（n = 3）或两者都不表达（n = 3），这表明前列腺肿瘤的某些生长模式与缺乏用于免疫检测的hK3或hK2的分泌或储存有关。这一说法似乎也适用于转移瘤。值得注意的是，4%的hK3阴性肿瘤可检测到hK2。由于hK3作为前列腺疾病血清标志物的重要性，本研究首次探讨了hK3和hK2在前列腺肿瘤免疫组织化学诊断中的相对重要性问题。我们得出结论，hK2可能为前列腺癌的诊断和特征描述增添新的信息。
